Yunkang Group (2325) Fundamentals 2026 — P/E 112.3x, Revenue Analysis | SniperIQ
Yunkang Group (2325) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of HK
Yunkang Group (2325) has a market capitalization of approximately HK
Yunkang Group's trailing twelve-month P/E ratio is 112.3x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Yunkang Group runs a net profit margin of 0.5%, a gross margin of 30.4%, and an operating margin of 5.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Yunkang Group reported revenue of ¥601M for fiscal year 2025, with net income of ¥3M and earnings per share (EPS) of 0.005. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Yunkang Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Yunkang Group carries a debt-to-equity ratio of 0.60x and a current ratio of 1.59x, with a market beta of -0.79. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yunkang Group (2325) the key facts are: market cap HK
Get Yunkang Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.